Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens
High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity
Graft source determines human hematopoietic progenitor distribution pattern within the CD34+ compartment
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis
GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT
Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT
Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution
Toll-like receptor 9, NOD2 and IL23R gene polymorphisms influenced outcome in AML patients transplanted from HLA-identical sibling donors
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update
Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT
Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT—results of a multicentre study
Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation
Cyclosporine levels and rate of graft rejection following non-myeloablative conditioning for allogeneic hematopoietic SCT
Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases
Immunomodulation by IFN-γ in patients with resistant infections and accompanying bronchiolitis obliterans following allo-SCT
Long-term remission in a child with refractory EBV+ hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV+-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy
Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone
Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma
Mycobacterial diseases in pediatric hematopoietic SCT recipients
What is the minimum level of donor chimerism necessary to sustain transfusion independence in thalassaemia?